EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV ‐1 initiating first‐line therapy: 5‐year follow‐up from two phase III studies

C Martorell, M Ramgopal, D Hagins, O Osiyemi, J R Arribas, M Berhe, Y Yazdanpanah, C Orkin, L Santiago, C Rosero, N Unger, H Liu und 3 weitere

HIV Medicine · 2025

DOI: 10.1111/hiv.70018 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift HIV Medicine, 2025. Verfasst von C Martorell und 14 weiteren Autor:innen. Beteiligte Einrichtung: The Research Institute, Springfield, Massachusetts, USA. Hauptthemen laut MEDLINE: Adenine, Anti-HIV Agents, Emtricitabine, HIV Infections. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Gilead Sciences, Inc, Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Black and Hispanic/Latine people are disproportionately affected by HIV‐1 and may have a greater risk of comorbidities than non‐Black and non‐Hispanic/Latine people with HIV. However, they have historically been underrepresented in HIV clinical studies. We aimed to assess the efficacy and safety of first‐line antiretroviral therapy with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) over 5 years in Black and Hispanic/Latine people with HIV.

Methods

We present two post hoc pooled analyses of participants who received B/F/TAF up to week 240 in studies 1489 (NCT02607930) and 1490 (NCT02607956). Outcomes were compared between self‐identified Black and non‐Black participants and between Hispanic/Latine and non‐Hispanic/Latine participants, including baseline characteristics, proportion with HIV‐1 RNA

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenineAnti-HIV AgentsEmtricitabineHIV InfectionsTenofovirAdultFemaleHumansMaleMiddle AgedAlanineBlack or African AmericanCD4 Lymphocyte CountDrug CombinationsFollow-Up StudiesHispanic or LatinoHIV-1PyridonesTreatment OutcomeViral LoadAmidesHeterocyclic Compounds, 3-RingPiperazines

Stichwörter der Autor:innen

BlackHispanicLatinebictegravirtenofovir alafenamide

Substanzen

AdenineAlanineAnti-HIV AgentsbictegravirDrug CombinationsEmtricitabinePyridonesTenofovirtenofovir alafenamideAmides

Autor:innen und Institutionen

  • The Research Institute, Springfield, Massachusetts, USA.
  • Midway Immunology and Research Center, Fort Pierce, Florida, USA.
  • Chatham CARE Center, Savannah, Georgia, USA.
  • Triple O Research Institute, West Palm Beach, Florida, USA.
  • Hospital Universitario La Paz, Madrid, Spain.
  • North Texas Infectious Diseases Consultants, Dallas, Texas, USA.

ORCID-Profile: J T Hindman

Förderung

  • Gilead Sciences, Inc
  • Gilead Sciences

Zitieren

APA

Martorell, C., Ramgopal, M., Hagins, D., Osiyemi, O., Arribas, J. R., Berhe, M., Yazdanpanah, Y., Orkin, C., Santiago, L., Rosero, C., Unger, N., Liu, H., Rogers, R., Hindman, J. T., & Wurapa, A. (2025). Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV ‐1 initiating first‐line therapy: 5‐year follow‐up from two phase III studies. HIV Medicine. https://doi.org/10.1111/hiv.70018

Vancouver

Martorell C, Ramgopal M, Hagins D, Osiyemi O, Arribas JR, Berhe M, et al. Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV ‐1 initiating first‐line therapy: 5‐year follow‐up from two phase III studies. HIV Medicine. 2025. doi:10.1111/hiv.70018

BibTeX
@article{Martorell2025,
  author = {Martorell, C and Ramgopal, M and Hagins, D and Osiyemi, O and Arribas, J R and Berhe, M and Yazdanpanah, Y and Orkin, C and Santiago, L and Rosero, C and Unger, N and Liu, H and Rogers, R and Hindman, J T and Wurapa, A},
  title = {Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV ‐1 initiating first‐line therapy: 5‐year follow‐up from two phase III studies},
  journal = {HIV Medicine},
  year = {2025},
  doi = {10.1111/hiv.70018}
}
Kostenlos starten →